Patent Cliff and M&A Trends

When patents expire, sales of legacy drugs drop sharply, prompting companies to pursue M&A to strengthen their portfolios. Consequently, the term “patent cliff” appears frequently in the market, describing the rapid revenue decline that follows loss of patent protection. Companies are seeking to mitigate this risk by rapidly acquiring new drug pipelines.

Shifts in Growth Strategies for Biopharma Companies

Firms that have reached growth limits through traditional R&D investment are opting for M&A to avoid patent‑expiration risk. Targets are often startups with early‑stage innovative technologies or next‑generation therapeutic candidates. This enables companies to complement existing product lines and secure new market entry opportunities.

Reconfiguration of Market Structure and Competitive Landscape

In segments where patent expirations are concentrated, large pharmaceutical companies are absorbing smaller firms, increasing market concentration. At the same time, startups possessing innovative technologies gain a foothold for rapid growth through partnerships with big pharma. This trend reshapes competition and signals to investors that new value chains merit close attention.

Implications for Investors and Researchers

An increase in M&A tends to concentrate R&D funding, creating a risk of under‑funding in certain innovative areas. Conversely, investors need to rigorously assess the target’s technological capabilities and potential synergies to adjust their portfolios. Over the long term, integrated pipelines will deliver new therapeutic options to the market.